DHR Danaher Corporation
$234.63 on 2026-10-28 · $164.9B · +9.7%
Danaher Corporation is a large cap Health Care company in Life Sciences Tools & Services. At $234.63 a share the market values it at $164.9 billion, up 10% over the past year.
Is DHR undervalued? Six plain tests
The rule asks what Buffett-style investors ask, using only Danaher Corporation’s own SEC filings: is it worth more than its price (upside of 20% or more to model value), is it a good business (a quality score of 0.5 or more), does it really make money (profits and positive cash earnings), and can it carry its debt (net debt under 3.5× operating income)?
It also skips cyclicals at peak margins, where today’s profits flatter the price. Read the method in plain English, exactly how each number is calculated, or why a margin of safety matters.
Other Health Care companies
- AMGNAmgen
- GILDGilead Sciences
- ABTAbbott Laboratories
- PFEPfizer
- ISRGIntuitive Surgical
- VRTXVertex Pharmaceuticals
- BMYBristol Myers Squibb
- MDTMedtronic
Who owns DHR? Funds managing over $100M report their US holdings every quarter on Form 13F. See the latest 13F filings as they land on SEC EDGAR.
Research only, not investment advice. Figures come from DHR’s SEC filings (trailing twelve months to 2026-09-25) and daily closes.